Conference Coverage

Ablation Safe, Effective for First-Line Atrial Fib Treatment


 

FROM THE ANNUAL MEETING OF THE HEART RHYTHM SOCIETY

The trial was sponsored by the Population Health Research Institute and McMaster University and Hamilton Health Sciences. It was supported by grant-in-aid from Biosense Webster. Dr. Morillo disclosed receiving consulting fees/honoraria/research grants from and/or being on a speakers bureau for Boehringer Ingelheim, Sanofi, Medtronic, Merck, St. Jude Medical, Boston Scientific, and Biosense Webster. Dr. Fogel disclosed that he has received grants for clinical research and educational activities from St. Jude Medical, Medtronic, and Guidant, and owns stock in Medtronic and Guidant.

Pages

Recommended Reading

FDA Advisers Endorse Subcutaneous ICD
MDedge Cardiology
Access to Personal Health Metrics Called a 'Civil Right'
MDedge Cardiology
Women's Stroke Risk Higher in AF, Regardless of Warfarin Use
MDedge Cardiology
Athletes With ICDs Have a Sporting Chance for Safe Play
MDedge Cardiology
Warfarin Self-Testing Boosts Time in Therapeutic Range
MDedge Cardiology
Coronary Dissection Drives MI Rates in Pregnancy
MDedge Cardiology
Independent Study Confirms Higher Riata ICD Lead Failure Rate
MDedge Cardiology
Fingolimod Label Advises ECG Monitoring at First Dose
MDedge Cardiology
Subcutaneous ICD Passes Efficacy, Safety Muster
MDedge Cardiology
ACC Urges Shift to Patient-Centered Care
MDedge Cardiology